



ISRAELI PUBLICATIONS

HILA MAGEN




> Am J Hematol. 2025 Apr 11. doi: 10.1002/ajh.27685. Online ahead of print.

The Impact of Melphalan Conditioning and CD34⁺ Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis

Eli Muchtar¹, Vaishali Sanchorawala², Hamza Hassan², Ute Hegenbart³, Stefan Schönland³, Hans C Lee⁴, Muzaffar Qazilbash⁴, Andrew Kin⁵, Jeffrey Zonder⁵, Eapen Jacob⁶, Francis Buadi¹, Angela Dispenzieri¹, David Dingli¹, Sally Arai⁷, Michelle Chin^{7 8}, Rajshekhar Chakraborty⁹, Suzanne Lentzsch⁹, Hila Magen¹⁰, Eden Shkury¹⁰, Caitlin Sarubbi¹¹, Heather Landau¹¹, Morie Gertz¹

Affiliations + expand

PMID: 40214172 DOI: 10.1002/ajh.27685



HILA MAGEN, MOSHE GATT




American Society of Hematology
2021 L Street NW, Suite 900,
Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
editorial@hematology.org

A phase 2, randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma

Tracking no: BLD-2024-027873R1

Sarah Holstein (University of Nebraska Medical Center, United States) Shebli Atrash (Levine Cancer Institute, United States) Hira Mian (McMaster University, Canada) Meletios Dimopoulos (National and Kapodistrian University of Athens, Greece) Fredrik Schjesvold (Oslo University Hospital, Norway) Rakesh Popat (NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, United Kingdom) Nishi Shah (Albert Einstein College of Medicine - Montefiore Medical Center, United States) Moshe Gatt (Hadassah Medical Center, Israel) Christian B. Gocke (Johns Hopkins University School of Medicine, United States) Laurent Frenzel (Service d'Hématologie Adulte et unité d'hémostase clinique, Hôpital Necker, Institut IMAGINE - INSERM U 1163 / CNRS ERL 8254, Paris France, France) Cyrille Touzeau (University hospital, France) Meral Beksac (Istinye University, Turkey) Salomon Manier (CHU Lille, France) Hila Magen (Sheba Medical Center, Israel) Patrick Travis (Highlands Oncology Group, United States) Omar Nadeem (Dana-Farber Cancer Institute, United States) Kaveri Suryanarayan (Takeda Development Center Americas, Inc. (TDCA), United States) Cheryl Li (Takeda Development Center Americas, Inc. (TDCA), United States) Shuli Li (Takeda Development Center Americas, Inc. (TDCA), United States) Allison Nelson (Takeda Development Center Americas, Inc. (TDCA), United States) Dasha Cherepanov (Takeda Development Center Americas, Inc., United States) Xavier Parot (Takeda Development Center Americas, Inc. (TDCA), United States) Dan Vogl (Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, United States)



JARCHOWSKY-DOLBERG OSNAT


Oncogenesis

www.nature.com/oncsis



ARTICLE **OPEN**

 Check for updates

Myeloma mesenchymal stem cells' bioenergetics afford a novel selective therapeutic target

Oded Komemi^{1,2}, Elina Orbuch^{1,2}, Osnat Jarchowsky-Dolberg^{2,3,4}, Yaron Shraga Brin⁵, Shelly Tartakover-Matalon^{2,6}, Metsada Pasmanik-Chor⁷, Michael Lishner^{1,2,4} and Liat Drucker^{1,2} 

© The Author(s) 2025



Yael Cohen


nature medicine



Article

<https://doi.org/10.1038/s41591-024-03485-7>

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial



MOSHE GATT, MERAV LEIBA



Contents lists available at [ScienceDirect](#)

Seminars in Hematology

journal homepage: www.elsevier.com/locate/seminhematol



Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenström macroglobulinemia related neuropathy

Shirley D'Sa^{a,*}, Jahanzaib Khwaja^a, Signy Chow^b, Meletios A. Dimopoulos^c, Irene Dogliotti^d, Moshe E. Gatt^e, Roman Hajek^f, Jindriska Lindsay^g, Giampaolo Merlini^h, Pierre Morelⁱ, Alessandra Tedeschi^j, Claudio Cerchione^k, Merav Leiba^l, Christopher J. Patterson^m, Steven P. Treon^m, Christian Buskeⁿ, Jeffrey V. Matous^o, Marzia Varettoni^p, Josephine M.I. Vos^q, Filip Eftimov^r, Michael P. Lunn^s, Efstathios Kastritis^c

